Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.21) per share. This is a 133.33 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $1.25 million in sales this quarter. This is a 64.57 percent decrease over sales of $3.54 million the same period last year.